Letter to the editor: Is transjugular intrahepatic portosystemic shunt the best treatment for adults without cirrhosis with extrahepatic portal vein obstruction and portal hypertension?
Caroline P. Lemoine, Riccardo Superina – 1 February 2022
Caroline P. Lemoine, Riccardo Superina – 1 February 2022
Haihong Wang, Biying Zhang, Ruiqi Li, Jiayuan Chen, Guojie Xu, Ying Zhu, Jiao Li, Qing Liang, Qingling Hua, Lanqing Wang, Lu Wen, Min Jin, Jun Fan, Dejun Zhang, Lei Zhao, Dandan Yu, Zhenyu Lin, Jinghua Ren, Tao Zhang – 1 February 2022
Randi J. Ryan, Timucin Taner, Julie K. Heimbach – 1 February 2022
Victor H. F. Lee, Tiffany C. L. Wong – 1 February 2022
Thomas Tu, Henrik Zhang – 1 February 2022
Hilary M. DuBrock, Kathryn T. Valle, Michael J. Krowka – 1 February 2022 – Patients with portopulmonary hypertension (POPH) have an increased cardiovascular and overall mortality risk when undergoing liver transplantation (LT). However, such risk is not captured in their Model for End‐Stage Liver Disease (MELD) laboratory score. POPH MELD exception criteria were established in 2006 with the aim of prioritizing these patients for LT prior to pulmonary hypertension (PH) progression and eventual right heart failure.
Chubin Luo, Haoyang Xin, Zhengjun Zhou, Zhiqiang Hu, Rongqi Sun, Na Yao, Qiman Sun, Uyunbilig Borjigin, Xia Wu, Jia Fan, Xiaowu Huang, Shaolai Zhou, Jian Zhou – 1 February 2022
Shari S. Rogal, Lissi Hansen, Arpan Patel, Nneka N. Ufere, Manisha Verma, Christopher D. Woodrell, Fasiha Kanwal – 31 January 2022
Shi‐You Jiang, Xinglin Yang, Zimo Yang, Jue‐Wan Li, Meng‐Qiang Xu, Yu‐Xiu Qu, Jing‐Jie Tang, Yun‐Feng Li, Liguo Wang, Yi‐Wen Shao, Xin‐Yuan Meng, Huili Hu, Bao‐Liang Song, Yu Rao, Wei Qi – 30 January 2022